Thrombocytopaenia in the Emergency Department: High-Yield MRCEM SBA Practice Questions Explained

Thrombocytopaenia sits at the intersection of basic science and acute clinical decision-making, which is precisely why it appears reliably in MRCEM SBA practice questions and rewards candidates who understand it mechanistically rather than by rote. A platelet count below 150 x 10⁹/L can represent an incidental laboratory finding in a well patient, a harbinger of catastrophic thrombosis in heparin-induced thrombocytopaenia (HIT), or the haematological footprint of sepsis-driven disseminated intravascular coagulation (DIC). For the UK emergency physician, distinguishing these entities rapidly and accurately is not an academic exercise; it is a competency that prevents harm. For the MRCEM Primary candidate, understanding the cellular biology, pharmacology, and pathophysiology underpinning each syndrome is the difference between answering the question correctly and selecting the distractor.

Definition and Clinical Context

Thrombocytopaenia is defined as a platelet count below 150 x 10⁹/L. Severity is conventionally stratified as mild (100 to 150 x 10⁹/L), moderate (50 to 100 x 10⁹/L), significant (20 to 50 x 10⁹/L), and severe (below 20 x 10⁹/L). Spontaneous mucocutaneous bleeding becomes a genuine risk below 20 x 10⁹/L, and the risk of spontaneous intracranial haemorrhage rises sharply below 10 x 10⁹/L. Epidemiologically, thrombocytopaenia is common in the ED: it accompanies sepsis, liver disease, alcohol excess, haematological malignancy, and a wide range of prescribed drugs. NICE guidance on haematological conditions and the broader haematology literature consistently emphasise that the aetiology, rather than the platelet number alone, drives management. For MRCEM Primary candidates, the exam tests whether you can map a clinical scenario to the correct mechanistic category and then select the appropriate immediate management step.

Platelet Biology: The Science Behind the SBA Question

Understanding thrombopoiesis is non-negotiable for the MRCEM Primary basic sciences component. Platelets are shed cytoplasmic fragments of megakaryocytes, large polyploid cells that differentiate from haematopoietic stem cells in the bone marrow under the influence of thrombopoietin (TPO). Each megakaryocyte generates approximately 1,000 to 3,000 platelets. TPO is produced constitutively by the liver; critically, free TPO (the fraction not bound to platelet GPIb receptors or megakaryocyte surfaces) is the biologically active pool. When platelet mass falls, more TPO remains unbound, stimulating further megakaryocyte differentiation. This negative-feedback loop is the pharmacological rationale for TPO receptor agonists such as romiplostim and eltrombopag, which are now used in refractory immune thrombocytopaenia (ITP).

Normal platelet lifespan is 7 to 10 days. Approximately one third of circulating platelets are sequestered in the spleen at any time. Senescent platelets are cleared by splenic and hepatic macrophages via Fc receptor and phosphatidylserine-recognition pathways. This physiology explains why hypersplenism (portal hypertension, infiltrative disorders) causes thrombocytopaenia through sequestration rather than destruction, and why splenomegaly on examination changes your differential immediately.

Primary haemostasis proceeds in a sequence that the MRCEM SBA exam tests in detail. Vessel injury exposes subendothelial collagen and von Willebrand factor (vWF). The platelet GPIb-IX-V receptor binds vWF, mediating adhesion under high shear. GPIIb/IIIa undergoes conformational activation and binds fibrinogen, crosslinking platelets into an aggregate. Dense granule release of ADP and serotonin, combined with alpha-granule release of fibrinogen, vWF, and factor V, amplifies the response. Thromboxane A2, synthesised via the COX-1 pathway, promotes vasoconstriction and further aggregation. This cascade explains why aspirin (irreversible COX-1 inhibition) prolongs bleeding time even at a normal platelet count, and why GPIIb/IIIa antagonists such as tirofiban can cause profound thrombocytopaenia.

Key Syndromes: Pathophysiology and ED Relevance

Immune Thrombocytopaenia (ITP)

ITP results from autoantibody-mediated (predominantly IgG anti-GPIIb/IIIa) platelet destruction by splenic macrophages, combined with impaired platelet production due to megakaryocyte antibody binding. It is a diagnosis of exclusion. In children, ITP is typically acute and self-limiting, often following a viral illness. In adults, it tends to be chronic. The emergency physician encounters ITP most often as a referral for active bleeding or an incidental finding below the treatment threshold. First-line therapy includes corticosteroids (prednisolone 1 mg/kg/day) and intravenous immunoglobulin (IVIg) for rapid platelet rise when urgent haemostasis is required. IVIg works by saturating Fc receptors on splenic macrophages, temporarily reducing platelet destruction.

Heparin-Induced Thrombocytopaenia (HIT)

HIT is one of the most clinically dangerous drug reactions encountered in the ED and one of the highest-yield topics for MRCEM SBA practice questions because its management is counterintuitive. HIT type 2 (the clinically significant form) is an immune reaction in which IgG antibodies form against complexes of platelet factor 4 (PF4) and heparin. These antibody-PF4-heparin complexes bind platelet Fc receptors, causing platelet activation, consumption, and paradoxical thrombosis despite the low platelet count. The thrombosis may be arterial or venous and is severe. Platelet count typically falls by more than 50% from baseline, occurring 5 to 10 days after heparin initiation (or within hours in patients previously sensitised). The 4Ts score (Thrombocytopaenia, Timing, Thrombosis or other sequelae, other causes of Thrombocytopaenia) stratifies pre-test probability. Immediate management requires cessation of ALL heparin (including flushes and heparin-coated catheters) and substitution with a non-heparin anticoagulant such as argatroban or fondaparinux. Platelet transfusion is contraindicated unless life-threatening haemorrhage is present, as it may fuel further thrombosis. The BMJ and haematology societies consistently highlight this counterintuitive management principle as a major source of clinical error.

Thrombotic Thrombocytopaenic Purpura (TTP)

TTP is a thrombotic microangiopathy caused by severe deficiency of ADAMTS13, the metalloprotease that cleaves ultra-large vWF multimers. Without ADAMTS13 activity, these multimers accumulate on endothelium, causing platelet-rich microthrombi in small vessels throughout the body. The classical pentad comprises microangiopathic haemolytic anaemia (MAHA, with schistocytes on blood film), thrombocytopaenia, neurological features (confusion, seizure, stroke), renal impairment, and fever. All five features are present in fewer than 10% of cases, so a high index of suspicion is required. MAHA plus thrombocytopaenia in the absence of another explanation should prompt urgent haematology referral and consideration of plasma exchange. TTP carries a mortality exceeding 90% if untreated; with plasma exchange it falls to around 10 to 20%. Plasma exchange removes the pathological antibodies against ADAMTS13 and replenishes functional enzyme. Platelet transfusion is again contraindicated, as it provides substrate for further microvascular thrombosis.

Disseminated Intravascular Coagulation (DIC)

DIC represents simultaneous excessive clotting and consumption coagulopathy, triggered most commonly in the ED by sepsis, major trauma, obstetric emergencies, or malignancy. Massive thrombin generation depletes platelets, fibrinogen, and clotting factors, while fibrinolysis produces elevated D-dimer. The blood film shows schistocytes. Laboratory findings include low platelets, prolonged PT and APTT, low fibrinogen, and elevated D-dimer. Management addresses the underlying cause. The Resuscitation Council UK sepsis guidance and major haemorrhage protocols direct component therapy: fresh frozen plasma (FFP), cryoprecipitate (for fibrinogen replacement), and platelet concentrates guided by clinical bleeding and laboratory values rather than by fixed thresholds alone.

ED Assessment and Management Algorithm

History should specifically identify: timing and rate of platelet fall, recent drug exposures (heparin, quinine, trimethoprim, vancomycin, GPIIb/IIIa inhibitors), recent infections, alcohol intake, symptoms of haematological malignancy, and personal or family history of bleeding disorders. Examination seeks petechiae, purpura, mucosal bleeding, lymphadenopathy, splenomegaly, and signs of the underlying cause.

Initial investigations include a full blood count with film (schistocytes suggest TMA), coagulation screen, fibrinogen, D-dimer, LDH, reticulocyte count, blood group and save, and renal and liver function. In the context of suspected HIT, the 4Ts score should be calculated and anti-PF4/heparin immunoassay sent urgently. ADAMTS13 activity and inhibitor levels are sent when TTP is suspected but must not delay plasma exchange.

Platelet transfusion thresholds follow NICE guidance on blood transfusion (NG24): prophylactic transfusion below 10 x 10⁹/L in stable patients; above 50 x 10⁹/L for most surgical procedures; above 100 x 10⁹/L for neurosurgery or posterior segment ocular surgery. These thresholds are adjusted upward in the context of active haemorrhage or platelet dysfunction.

How the MRCEM SBA Exam Tests This Topic

The MRCEM Primary syllabus maps directly to basic sciences including haematology, pharmacology, and physiology. The RCEM curriculum requires candidates to demonstrate understanding of the mechanisms underlying common haematological emergencies. In practice, MRCEM SBA practice questions on thrombocytopaenia tend to use one of several recurring stem types. A patient on unfractionated heparin develops a 60% platelet count drop on day 8 and a new DVT: the question asks for the most appropriate next step, with distractor options including increasing heparin dose, giving platelet transfusion, or switching to low molecular weight heparin (also contraindicated in HIT). A second common stem presents a patient with confusion, anaemia, thrombocytopaenia, and renal impairment, asking for the most likely diagnosis or the investigation that would confirm it (ADAMTS13 activity). A third tests platelet transfusion thresholds in a specific clinical context. Candidates who understand mechanism answer these correctly without hesitation; those who have memorised lists often select a plausible but mechanistically incorrect answer.

The MRCEM SBA exam format rewards the ability to reason from first principles. Recognising that HIT is prothrombotic, that TTP is worsened by platelet transfusion, and that IVIg blocks Fc-receptor clearance are the mechanistic anchors that unlock correct answers across multiple question variants. For structured MRCEM Primary revision, working through a dedicated question bank with detailed explanations is more efficient than passive reading alone.

Revision Pearls: High-Yield Facts for MRCEM SBA

1. TPO negative feedback: Free TPO stimulates platelet production. In ITP, platelet destruction is high but liver TPO production is normal; paradoxically, TPO levels may not be markedly elevated because megakaryocyte TPO binding is preserved. In aplastic anaemia, free TPO rises substantially.
2. HIT is prothrombotic: Never transfuse platelets in HIT unless life-threatening haemorrhage is occurring. Switch to argatroban (direct thrombin inhibitor) or fondaparinux (factor Xa inhibitor). Low molecular weight heparin is cross-reactive and must not be substituted.
3. ADAMTS13 in TTP: Activity below 10% confirms TTP. Initiate plasma exchange before the result returns if clinical suspicion is high. Do not transfuse platelets.
4. Schistocytes on blood film indicate microangiopathic haemolytic anaemia and narrow the differential to TTP, haemolytic uraemic syndrome (HUS), DIC, or malignant hypertension.
5. Drug-induced thrombocytopaenia: Quinine, vancomycin, trimethoprim, and GPIIb/IIIa inhibitors are high-yield culprits. The mechanism is hapten-mediated antibody formation or direct marrow suppression (cytotoxics, alcohol, linezolid).
6. Splenic pooling: Splenomegaly can sequester up to 90% of circulating platelets (normally one third). This reduces the circulating count without reducing total body platelet mass.
7. DIC coagulation profile: Low platelets, low fibrinogen, elevated D-dimer, prolonged PT and APTT. Contrast with liver disease, where D-dimer and fibrinogen may be less severely deranged in proportion.
8. IVIg in ITP: Acts by Fc receptor blockade on splenic macrophages, reducing platelet clearance. Onset within 24 to 48 hours, effect lasts weeks. Used when rapid platelet rise is required (preoperatively or for active bleeding).

Common Pitfalls: Where Candidates Lose Marks

• Selecting LMWH as a safe alternative to unfractionated heparin in HIT. It is not; both are contraindicated.
• Transfusing platelets in TTP or HIT without a haemorrhagic indication. This is harmful and a discriminating distractor.
• Confusing TTP with HUS: HUS is predominantly renal-limited, associated with Shiga-toxin-producing Escherichia coli, and occurs mainly in children. ADAMTS13 activity is normal or near-normal in HUS.
• Missing the significance of the blood film. Schistocytes are the key finding that distinguish thrombotic microangiopathy from other causes of thrombocytopaenia.
• Applying a fixed platelet transfusion threshold without considering the clinical context. The threshold for neurosurgery (above 100 x 10⁹/L) differs substantially from the prophylactic threshold in a stable haematology patient (below 10 x 10⁹/L).
• Failing to stop all heparin sources in suspected HIT, including line flushes and heparin-bonded catheters.

How EM Learning Centre Supports Your MRCEM Primary Revision

Thrombocytopaenia is one of many haematological and basic science topics that appear with regularity in the MRCEM SBA practice questions you will encounter on exam day. Mastering it requires integrating platelet biology, drug pharmacology, clinical syndrome recognition, and guideline-directed management into a coherent framework that you can apply under time pressure. The EM Learning Centre homepage provides access to a structured, curriculum-mapped question bank and teaching resources built specifically for UK emergency medicine trainees preparing for the MRCEM Primary and beyond.

Our question bank includes detailed, consultant-written explanations for every answer option, so you understand not just what the correct answer is but why the distractors are wrong. This is the approach that builds the mechanistic reasoning the MRCEM SBA exam rewards. If you are looking for a comprehensive, evidence-grounded MRCEM Primary revision course at EM Learning Centre, our platform covers the full basic sciences curriculum including haematology, pharmacology, anatomy, physiology, and pathology, with content updated to reflect current NICE and Royal College of Emergency Medicine guidance. Work through the thrombocytopaenia questions, review the explanations, and test your understanding against the clinical scenarios described above. That cycle of practice, explanation, and consolidation is how you convert knowledge into marks.

References

1. Royal College of Emergency Medicine. RCEM Curriculum and Syllabus. rcem.ac.uk
2. National Institute for Health and Care Excellence. Blood Transfusion (NG24). nice.org.uk
3. National Institute for Health and Care Excellence. Clinical Knowledge Summaries: Thrombocytopaenia. nice.org.uk
4. Resuscitation Council UK. Sepsis and Major Haemorrhage Guidance. resus.org.uk
5. The BMJ. Heparin-induced thrombocytopaenia: clinical review and management principles. bmj.com
6. British National Formulary. Anticoagulants and haematological agents. bnf.nice.org.uk